Talking Rain Boosts Convenience Store Presence with New C-Store VP, Chelsea Sobran

Talking Rain Beverage Company®, makers of the No. 1 sparkling water brand, Sparkling Ice ®, today announced the hiring of Chelsea Sobran, VP of Convenience Channel, who brings a deep understanding of the consumer landscape and spearheads the company's strategic growth in the convenience store market.
'As with other Talking Rain distribution channels, the convenience store channel strategy revolves around meeting our consumers where they are. When our consumers are on the go, they find the convenience store cold vault a great place to pick out and try new products,' said Sobran. 'Given the pent-up demand for better-for-you beverages, and Talking Rain's wide range of offerings, we expect to see Talking Rain more than double its c-store sales over the next three years.'
Sobran's role entails growing the company's sales footprint by developing and maintaining relationships with the largest and most complex retailers in the convenience channel and ensuring Talking Rain products look irresistible on the shelf. Sobran has seen a marked transition take place in beverage options at c-stores, first expanding from regular soda to diet soda, and most recently toward better-for-you beverages.
Sobran joins the Talking Rain team at the beginning of a year dedicated to accelerated growth through new flavors and product offerings, as well as an expansion of partnerships. Most recently, Talking Rain announced the launch of its Sparkling Ice STARBURST RED PACK, a continuation of the brand's partnership with STARBURST, which first became a runaway hit in 2024. Flavor fans can expect several new Talking Rain products and formats to launch in 2025.
Before joining Talking Rain, Sobran spent ten years at Nestlé Waters North America, where she held roles in sales, analytics and marketing across both Canada and the United States, before moving on to serve as the sales VP at Keurig Dr Pepper. There she developed and led a sales team for the commercial coffee business unit across convenience, foodservice and hospitality channels.
'We are excited to welcome Chelsea to the team, marking another strategic investment in our company's expansive growth trajectory,' said Ken Sylvia, CEO of Talking Rain Beverage Co. 'Chelsea brings a wealth of expertise that will be pivotal as we expand our presence and introduce new Sparkling Ice flavors, along with other Talking Rain products, to the convenience sector nationwide. This move ensures that our flavorful beverages are more accessible to consumers everywhere.'
Learn more about Talking Rain at https://www.talkingrain.com.
Talking Rain, the makers of Sparkling Ice®, is a family-owned company based in Preston, Washington. Through nearly four decades of redefining the sparkling water category, Talking Rain has crafted a remarkable collection of full-flavored, better-for-you beverages, including the #1 sparkling water brand in the U.S., Sparkling Ice (also available in +Caffeine and +Energy). Talking Rain drinks have zero sugar, are enriched with vitamins and antioxidants, and come in a delicious array of bold flavors. Talking Rain believes in sharing its success to support healthy communities, personal wellbeing, and greater inclusivity. We live life in full flavor and believe the world should, too.
Media Contact
Annie Alley
206-466-2713

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

3 hours ago

• Business Upturn

Andreas Christensen's exit nearly confirmed as Director Deco gives a statement

Barcelona's centre-back named Andreas Christensen is expected to leave the club this current summer transfer window. By Ravi Kumar Jha Published on June 23, 2025, 08:31 IST Barcelona's centre-back named Andreas Christensen is expected to leave the club this current summer transfer window as the club Director Deco confirmed in a statement. Christensen have been a good performer since joining the side, but now he will have to leave. The defender is now actively looking for new clubs to join in. Barcelona centre-back Andreas Christensen is expected to depart the club during the current summer transfer window, Director Deco has confirmed. The Danish international, who joined the Catalan giants from Chelsea in 2022, has been a consistent performer in defence over the past two seasons. However, Barcelona's current squad depth in the centre-back position has forced the club to make a difficult decision. 'We've five centre-backs, one needs to leave because the position is overcrowded,' Deco said in a statement, as reported by transfer expert Fabrizio Romano. Despite his solid contributions, Christensen will now seek opportunities elsewhere as he begins the search for a new club. With top-level experience in both La Liga and the Premier League, the 28-year-old is expected to attract significant interest in the market. Ahmedabad Plane Crash Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at

Business Wire

9 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Yahoo

2 days ago

• Yahoo

Florian Wirtz explains why he joined Liverpool as huge ambitions revealed after £116m transfer

Liverpool have confirmed the club-record signing of Bayer Leverkusen forward Florian Wirtz. The 22-year-old Germany international moves for an initial fee of £100million, which could rise to £116m with performance-based add-ons. Advertisement That figure would pip the current British transfer record, set when Chelsea spent £115m to sign Brighton and Ecuador midfielder Moises Caicedo in 2022. Wirtz has signed a five-year contract with Liverpool reportedly worth £200,000 per week. 'I feel very happy and very proud,' Wirtz told Liverpool's official website. 'Finally it's done and I was waiting for a long time – finally it's done and I am really happy. 'I'm really excited to have a new adventure in front of me. This was also a big point of my thoughts: that I want to have something completely new, to go out of the Bundesliga and to join the Premier League. Advertisement 'I will see how I can perform there. I hope I can do my best. I spoke also with some players who played there and they told me that it's perfect for me and every pitch is perfect, you can enjoy every game. I'm really looking forward to playing my first game.' He added: 'I would like to win everything every year! First of all, we have to do our work, I have to make my work. 'In the end, we want to be successful. Last season they won the Premier League so my goal is for sure to win it again and also to go further in the Champions League. I'm really ambitious.' The signing is a considerable statement of intent from Liverpool and Arne Slot ahead of their Premier League title defence. Wirtz has established himself as one of Europe's top talents in recent seasons, playing a key role in Leverkusen's invincible domestic double in 2023-24. Advertisement He racked up 16 goals and 15 assists in 45 appearances across all competitions last season as Leverkusen finished second in the Bundesliga, 13 points shy of champions Bayern Munich. Wirtz made his professional debut with Leverkusen in 2020 as an academy graduate, going on to make 197 appearances for the club. He also has 31 international caps to his name. Liverpool faced considerable competition for Wirtz's signature, fighting German champions Bayern for several months before eventually pricing them out of the move. This transfer will not be the extent of Liverpool's summer business, amid reports they could break the British transfer record for a second time with a £150m move for prolific Newcastle striker Alexander Isak. Advertisement They will continue to negotiate with Leverkusen, who are looking to sign defender Jarell Quansah. Liverpool have already signed Wirtz's Leverkusen team-mate Jeremie Frimpong, plus goalkeepers Giorgi Mamardashvili and Armin Pecsi. They have also agreed a £40m deal with Bournemouth for left-back Milos Kerkez and are reportedly plotting a 'significant' offer for Crystal Palace captain Marc Guehi.